Adding on in fibrosis

Bristol-Myers Squibb Co.’s deal to license worldwide rights to Nitto Denko Corp.’s antifibrotic siRNA therapy gives the pharma one of industry’s broadest fibrosis pipelines - and the ability to test multiple combinations.

BMS now owns or has options to acquire fibrosis programs with five mechanisms, none of which reside in the pipelines of major competitors. Gilead Sciences Inc. and Allergan plc each have three clinical fibrosis programs...